Plateletcrit may predict no-reflow after saphenous vein graft interventions in patients with non-ST elevation

Cafer Panç1, Emir Derviş, İsmail Gürbak

  • 1Department of Cardiology, University of Health Sciences, Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, İstanbul, Turkey.

Insights

Plateletcrit (PCT) may predict no-reflow during saphenous vein graft interventions in non-ST elevation myocardial infarction patients. Higher PCT levels indicate an increased risk of developing no-reflow, aiding in patient stratification.

Area of Science:

  • Cardiology
  • Hematology
  • Interventional Cardiology

Background:

  • Saphenous vein graft (SVG) percutaneous coronary interventions (PCIs) carry risks like distal embolization and no-reflow.
  • Platelets play a key role in thrombus formation and the no-reflow phenomenon.
  • Previous studies suggest a link between plateletcrit (PCT) and adverse cardiovascular outcomes.

Purpose of the Study:

  • To evaluate if PCT can predict the occurrence of no-reflow in patients with non-ST elevation myocardial infarction (NSTEMI) undergoing PCI for SVG disease.
  • To identify patients at higher risk for no-reflow during SVG PCI procedures.

Main Methods:

  • Retrospective analysis of 181 NSTEMI patients who underwent PCI for SVG disease.
  • Recording of platelet indices upon admission.
  • Division of patients into no-reflow (n=32) and normal reflow (n=149) groups.

Main Results:

  • The no-reflow group exhibited significantly higher PCT (0.254 vs. 0.224, P=0.020) and platelet count (265.4 vs. 233, P=0.011).
  • ROC analysis identified a PCT cut-off of 0.230 for predicting no-reflow (68.8% sensitivity, 51.0% specificity).
  • Multivariate analysis confirmed PCT as an independent predictor of no-reflow (OR: 5.091, CI: 1.356-19.116, P=0.016).

Conclusions:

  • PCT is a potential independent predictor of no-reflow in NSTEMI patients undergoing SVG PCI.
  • Elevated PCT levels may help identify patients at risk for no-reflow complications.
  • PCT can be a valuable tool for risk stratification in this patient population.